# 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC

> **NCT05980702** · PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 192 (estimated)

## Conditions studied

- HNSCC
- Oral Cancer
- PD-1

## Interventions

- **DRUG:** Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
- **DRUG:** Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses

## Key facts

- **NCT ID:** NCT05980702
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-04
- **Primary completion:** 2025-04-03
- **Final completion:** 2030-04-03
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2023-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05980702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05980702, "4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05980702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*